Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH. 2014

Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
Department of Chemistry, Graduate School of Science and Engineering, Saga University, 1 Honjo-machi, Saga 840-8502, Japan.

While stimulation of formyl peptide receptors (FPRs) on the surface of human neutrophils induces several immune responses, under conditions of continuous activation of the receptor by agonists such as formyl-Met-Leu-Phe-OH (fMLP), neutrophil-dependent tissue damage ensues. Thus, FPR antagonists could be anticipated as drugs for FPR-related disease. In this study, Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH (Boc-FlFlF), one of several FPR subtype selective antagonists, was chosen and the positions at the Phe residues were optimized. We found that substitution with unnatural amino acids resulted in an improvement of two orders of magnitude. The most potent antagonist indicated FPR subtype selectivity at 1 μM. In addition to finding a potent antagonist, the structure-activity trends observed in this study should be valuable in designing a new type of FPR subtype selective antagonist.

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017136 Ion Transport The movement of ions across energy-transducing cell membranes. Transport can be active, passive or facilitated. Ions may travel by themselves (uniport), or as a group of two or more ions in the same (symport) or opposite (antiport) directions. Antiport,Ion Cotransport,Ion Exchange, Intracellular,Symport,Uniport,Active Ion Transport,Facilitated Ion Transport,Passive Ion Transport,Cotransport, Ion,Exchange, Intracellular Ion,Intracellular Ion Exchange,Ion Transport, Active,Ion Transport, Facilitated,Ion Transport, Passive,Transport, Active Ion,Transport, Ion
D044042 Receptors, Formyl Peptide A family of G-protein-coupled receptors that was originally identified by its ability to bind N-formyl peptides such as N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE. Since N-formyl peptides are found in MITOCHONDRIA and BACTERIA, this class of receptors is believed to play a role in mediating cellular responses to cellular damage and bacterial invasion. However, non-formylated peptide ligands have also been found for this receptor class. Chemotactic Peptide Receptor,Chemoattractant Receptor,F-Chemotactic Peptide Receptor,FMLP Receptor,Formyl Peptide Receptor,N-Formylmethionyl Peptide Receptor,N-formyl Hexapeptide Receptor,Receptor, Chemotactic Peptide,fMet-Leu-Phe Receptor,F Chemotactic Peptide Receptor,Formyl Peptide Receptors,Hexapeptide Receptor, N-formyl,N Formylmethionyl Peptide Receptor,N formyl Hexapeptide Receptor,Peptide Receptor, Chemotactic,Peptide Receptor, N-Formylmethionyl,Peptide Receptors, Formyl,Receptor, Chemoattractant,Receptor, F-Chemotactic Peptide,Receptor, FMLP,Receptor, Formyl Peptide,Receptor, N-Formylmethionyl Peptide,Receptor, N-formyl Hexapeptide,Receptor, fMet-Leu-Phe,fMet Leu Phe Receptor
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell

Related Publications

Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
August 2020, Angiogenesis,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
August 1993, Acta crystallographica. Section C, Crystal structure communications,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
June 1999, Biochimica et biophysica acta,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
December 2023, European journal of medicinal chemistry,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
December 2000, The Journal of biological chemistry,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
December 2007, Inflammation,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
March 1993, Proceedings of the National Academy of Sciences of the United States of America,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
August 2017, Journal of medicinal chemistry,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
March 1979, International journal of peptide and protein research,
Ryo Hayashi, and Toshiki Kitajima, and Hikaru Mizuguchi, and Miki Fujimoto, and Aya Yamaguchi, and Shuichiro Koga, and Yuya Koga, and Satoshi Osada, and Hiroaki Kodama
February 1982, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!